CerbACT Asia empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research & clinical development strategies, combining the strengths of Cerba Research and ACT Genomics. We are enabled by cutting edge technologies in Flow Cytometry (FCM), Immunohistochemistry (IHC), and PBMC/cell isolations, while functioning as a central laboratory in the APAC region. Working with biotech, pharma, government and nongovernmental organizations, our team is ready to turn precision medicine into action!

CerbACT Asia

Click here to download the flyer

Reach out to our experts and discover how we can help advance your research

Contact Us

Discover Cerba Research and our clinical trials

Click here to download the fact sheet

Reach out to our experts and discover how we can help advance your research

Contact Us

The coronavirus is not the first infectious disease that has forced clinical trials to adapt. Zika, Ebola and other diseases called for the world to adjust and collaborate global research efforts. With COVID-19, the rapid spread and impact on global healthcare systems forced us to change our trial management and accelerate our processes like never before. The global research community have already discovered and developed several tests and vaccines in record time through collaboration. Yet we are still working on predictive biomarker testing to identify people who are at the most risk of developing severe symptoms, epidemiological, vaccine and genetic studies.

To facilitate testing, research, and innovation and to ensure trials continued, Cerba Research and Cerba Healthcare adapted our capabilities and facilities to push research continuity.

Watch this webinar and discover the answers to these questions:

• Did we succeed, how fast did we adapt and are we ready to face a new pandemic crisis in the future?
• How did we maintain the high security and confidence of testing, and what did our reactivity and proactivity mean in the context of a health crisis?

Reach out to our experts and discover how  we can help you advance your clinical trial

Contact Us

Pharmaceutical and biotech companies are dealing with a paradigm shift in drug development as the industry embraces more personalized, complex, and expensive cell therapies.

With some therapeutics proving ineffective in as many as 75% of patients, the need for precision medicine is clear, as is the benefit of using selection biomarkers in the drug development process where success rates can triple. Consequently, companies are balancing the increased demands for unique, esoteric testing with budget restrictions and geographical coverage.

In the quest to accelerate drug discovery to market and reduce costs, the industry continues ever further with externalization and outsourcing of drug development. Outsourcing penetration is expected to expand, as pharmaceutical and biotech companies must continue to replenish their pipeline and, hence, are incessantly looking for new sources of innovation.

Read the full article here

Reach out to our experts to discover how we can help advance your clinical trial

Contact Us

Africa has immense potential as an emerging market, and pharmaceutical and biotech companies have many avenues to leverage from Barc Lab’s African footprint for running clinical trials.

Accounting for nearly 17% of the global population, and representing a diverse population of potential patients, the African continent offers many of the best conditions for conducting clinical trials. Importantly, a number of diseases – particularly those defined as neglected and tropical – are endemic to the developing world, which includes Africa.

Despite all these advantages, Africa contributes to less than 3% of the number of clinical trials. The lack of infrastructure, cultural barriers and dedicated staff, and misunderstanding of requirements to work in the region, are simultaneously causing a burden to conducting clinical trials within Africa. However, Barc Lab believes that Africa offers an enormous opportunity for pharmaceutical and biotech companies searching for low-cost study sites, low risk of litigation and a diverse patient population. The latter makes Africa an ideal location for research, as the diseases of affluence and poverty are prevalent.

Moreover, the majority of patients to be potentially enrolled in clinical trials have not received any previous treatment for their disease – either because it is not available or they cannot afford it – facilitating patient recruitment to a great extent.

Read the full article here

Reach out to our experts and discover how we can help advance your clinical trial

Contact Us

Innovations in precision medicine have the potential to transform healthcare and create tailor-made medical solutions for patients. Clinical Trials Insight talks to Mario Papillon, CEO of Cerba Research, about how his organisation is helping patients receive novel treatments faster by making clinical trials more efficient. This agility, combined with global access to industry-leading laboratories, has been key in the fight against Covid-19, and will continue to be an imperative in the new reality in which future clinical trials will have to exist.

Read the full article here

Reach out to our experts and discover how we can help you advance your clinical trial

Contact Us

Cerba Research is the Belgian division of the French Group Cerba Healthcare. The company facilitates clinical studies and lab tests, and supports the entire logistics chain. What are the developments in this market and what does the future bring?

Cerba Research may not be known to the general public, but the company does have reputable pharmaceutical companies as customers. Why do they join forces with Cerba Research, and which added value can the organization in Ghent offer? Pharmaceutical companies may have testing capabilities, but the entire logistics process that surrounds it is our specialty. For example, how can you distribute sample kits quickly, efficiently and without issues? That’s what we are perfectly suited to do. We gather all the materials needed to collect samples and deliver them neatly in kits. We also process and prepare all the patient data paperwork. Once all the data has been received, we order lab tests, in our own labs or through partners. The results are then made available to the client via PDF’s and our electronic portal.

Click here to read the full article

Reach out to our experts and discover how we can help you advance your clinical trial

Contact Us

A staggering number of clinical trials fail to enroll enough patients. Most of the time, it’s not because the patients don’t exist; it’s finding them that can be difficult.

This is a struggle that Professor Karine Lacombe’s team at the infectious and tropical diseases department of Saint-Antoine Hospital in Paris know all too well. In addition to overseeing the department’s clinical research activities, she is also an investigator and co-investigator of several national and international cohort studies and multi-center trials in the field of HIV-viral hepatitis coinfection and Covid-19, and is a scientific manager of interventional studies in public health.

Professor Lacombe spoke to Clinical Trials Arena about the difficulties of patient recruitment and a new application the department is using to boost patient numbers. She starts by outlining her team’s previous approach to recruitment, which involved total reliance on the department’s own digital database of inpatient records.

“To find patients for a trial, we go into the database and use the inclusion criteria to ask if we have patients that respond to the eligibility criteria,” Professor Lacombe explains. “The problem with this approach is that we can only act on patients who are followed for chronic infection, whereas some of the trials we have recently started require patients who are in an ambulatory setting.”

For help finding outpatients, the hospital started contacting colleagues in the wider community who could search databases of their own. Often, however, these individuals didn’t have time to assist.

“It has been very difficult to identify the required patients,” says Professor Lacombe. “This approach has not only delayed inclusions; in some trials we have not even been able to include patients, especially for Covid-19 trials that addressed ambulatory care or prevention. That’s why we had to change.”

Download the full article to discover how Cerba Research has helped Saint-Antoine Hospital boost patient recruitment with medical laboratory data

Article – How Saint-Antoine Hospital is boosting patient recruitment with medical laboratory data

Click here to download the full article

Reach out to our experts and discover how we can help you advance your research

Contact Us

The new big data application is reshaping clinical trials. Someone on the shopfloor spots an improvement or better way of doing things that snowballs into a business; it’s a familiar approach to innovation and entrepreneurship. Indeed, many big technology firms deliberately encourage this behaviour.

But it’s less common for a practising doctor to create a successful technology solution. But let that be the story of Adrien Ko, who hit the idea for his data-driven patient recruitment start-up while he was supervising a lab for Cerba Healthcare in France.

Article – The new big data application that is reshaping clinical trials

Click here to read the full article

Reach out to our experts and discover how we can help you advance your research

Contact Us

Patient recruitment has always been a challenge for clinical research, with most clinical trials failing to enrol enough participants in time, let alone the right patients. When trying to get a study initiated, enrolment challenges are more than just inconvenient; they can also be incredibly costly. With close to 100% of studies requiring timeline extensions for recruitment, it’s no surprise the global clinical trials industry spends more than $2 billion on enrolment efforts and delays each year.

Find out how Cerba Research is leveraging the biological and clinical data from patients visiting its parent company’s network of clinics.

Article – Matching patients to trials

Click here to download the article

Reach out to our experts and discover how we can help you advance your clinical trial

Contact Us